On this page:Overview Publications Researchers Institutions Open access

PICO Portalanswers from OpenAlex

Alector (United States)

InstitutionResearch output, impact & collaborations

Alector (United States) is a institution indexed in PICO Portal from OpenAlex.

What is known about Alector (United States)?

PICO Portalrecord summary

Alector (United States) is a research organisation in San Francisco, US. OpenAlex records 179 works and 20,612 citations for it. 116 researchers list it as their most recent affiliation.

How many works does Alector (United States) have?

PICO Portalindexed works

Alector (United States) has 179 works in the PICO Portal index. The count is the OpenAlex total, not the number of papers listed on this page.

See the works listed for Alector (United States) →

How many citations does Alector (United States) have?

PICO Portalcitation count

Alector (United States) has 20,612 citations in the OpenAlex counts PICO Portal stores.

See the listed works for Alector (United States) →

How many researchers are at Alector (United States)?

PICO Portalresearcher count

Alector (United States) has 116 researchers in the PICO Portal index.

See the researchers listed on this page →

What is the average h-index at Alector (United States)?

PICO Portalavg h-index

Alector (United States) has an average h-index of 71.3 in OpenAlex.

Open the OpenAlex record →

What is the ROR of Alector (United States)?

PICO Portalror

The ROR for Alector (United States) is on the source record.

Open the ROR →

What is the OpenAlex record for Alector (United States)?

PICO Portalopenalex

The OpenAlex for Alector (United States) is on the source record.

Open the OpenAlex →

Who are the most-cited researchers behind Alector (United States)?

PICO Portaltop researchers by citations

Alan Sandler · Lung Cancer Treatments and Mutations

218 works43,717 citations

Arnon Rosenthal · Nerve injury and regeneration

129 works31,153 citations

Robert Paul · HIV Research and Treatment

534 works24,479 citations

What are the most-cited papers on Alector (United States)?

PICO Portalmost cited works

Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer

Alan Sandler, Robert J. Gray, Michael C. Perry, Julie R. Brahmer, Joan H. Schiller, Afshin Dowlati, Rogério Lilenbaum, David H. Johnson

New England Journal of Medicine. 20065,784 CitationsOPEN ACCESS

Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial

Achim Rittmeyer, Fabrice Barlési, Daniel Waterkamp, Keunchil Park, Fortunato Ciardiello, Joachim von Pawel, Shirish M. Gadgeel, Toyoaki Hida, Dariusz M. Kowalski, Manuel Cobo, Diego Cortinovis, Joseph W. Leach, Jonathan Polikoff, Carlos H. Barrios, Fairooz F. Kabbinavar, Osvaldo Arén Frontera, Filippo de Marinis, Hande Turna, Jong-Seok Lee, Marcus Ballinger, Marcin Kowanetz, Pei He, Daniel S. Chen, Alan Sandler, David R. Gandara

The Lancet. 20164,795 CitationsOPEN ACCESS

Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC

Mark A. Socinski, Robert M. Jotte, Federico Cappuzzo, Francesco Orlandi, Daniil Stroyakovskiy, Naoyuki Nogami, Delvys Rodríguez‐Abreu, Denis Moro‐Sibilot, Christian A. Thomas, Fabrice Barlési, Gene Grant Finley, Claudia Kelsch, Anthony Lee, Shelley Coleman, Yu Deng, Yijing Shen, Marcin Kowanetz, Ariel López-Chávez, Alan Sandler, Martin Reck

New England Journal of Medicine. 20183,781 CitationsOPEN ACCESS

First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer

Leora Horn, Aaron S. Mansfield, Aleksandra Szczęsna, Libor Havel, Maciej Krzakowski, Maximilian J. Hochmair, Florian Huemer, György Losonczy, Melissa L. Johnson, Makoto Nishio, Martin Reck, Tony Mok, Sivuonthanh Lam, David S. Shames, Juan Liu, Beiying Ding, Ariel López-Chávez, Fairooz F. Kabbinavar, Wei Lin, Alan Sandler, Stephen V. Liu

New England Journal of Medicine. 20183,565 CitationsOPEN ACCESS

Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial

Louis Fehrenbacher, Alexander I. Spira, Marcus Ballinger, Marcin Kowanetz, Johan Vansteenkiste, Julien Mazières, Keunchil Park, David C. Smith, Á. Artal, C. Lewanski, Fadi Braiteh, Daniel Waterkamp, Pei He, Wei Zou, Daniel S. Chen, Jing Yi, Alan Sandler, Achim Rittmeyer

The Lancet. 20162,812 Citations

How much of the research on Alector (United States) is open access?

PICO Portalopen access share

75%OPEN ACCESS

Gold

Green

17%

Hybrid

Bronze

50%

Closed

25%